Solubility advantage from amorphous etoricoxib solid dispersions

References

• Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86:1–12
   PubMed Web of Science ®Google Scholar
• Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev 2001;48:27–42
   PubMed Web of Science ®Google Scholar
• Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000;17:397–404
   PubMed Web of Science ®Google Scholar
• Murdande SB, Pikal MJ, Shanker RM, et al. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 2010;99:1254–64
   PubMed Web of Science ®Google Scholar
• Murdande SB, Pikal MJ, Shanker RM, et al. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. J Pharm Sci 2010;27:2704–14
   Google Scholar
• Chawla G, Bansal AK. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur J Pharm Sci 2007;32:45–57
   PubMed Web of Science ®Google Scholar
• Turnbull D, Fisher JC. Rate of nucleation in condensed systems. J Chem Phys 1949;17:71
   Web of Science ®Google Scholar
• Konno H, Handa T, Alonzo DE, et al. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 2008;70:493–9
   PubMed Web of Science ®Google Scholar
• Mura P, Faucci MT, Manderioli A, et al. Thermal behaviour and dissolution properties of naproxen from binary and ternary solid dispersions. Drug Dev Ind Pharm 1999;25:257–64
   PubMed Web of Science ®Google Scholar
• Mura P, Manderioli A, Bramanti G, et al. Properties of solid dispersion of naproxen in various poly(ethylene glycol)s. Drug Dev Ind Pharm 1996;22:909–16
   Web of Science ®Google Scholar
• Silva TD, Arantes VT, Resende JALC, et al. Preparation and characterization of solid dispersion of simvastatin. Drug Dev Ind Pharm 2010;36:1348–55
   PubMed Web of Science ®Google Scholar
• Simonelli AP, Meshali MM, El-Gawad AHA, et al. Effect of some polymers on the physico-chemical and dissolution properties of hydrochlorothiazide II. Drug Dev Ind Pharm 1994;20:2741–52
   Web of Science ®Google Scholar
• Dontireddy R, Crean AM. A comparative study of spray-dried and freeze-dried hydrocortisone/polyvinyl pyrrolidone solid dispersions. Drug Dev Ind Pharm 2011;37:1141–9
   PubMed Web of Science ®Google Scholar
• Jang DJ, Sim T, Oh E. Formulation and optimization of spray-dried amlodipine solid dispersion for enhanced oral absorption. Drug Dev Ind Pharm 2012 (in press); doi: 10.3109/03639045.2012.723218
   Google Scholar
• Feng J, Xu L, Gao R, et al. Evaluation of polymer carriers with regard to the bioavailability enhancement of bifendate solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm 2012;38:735–43
   PubMed Web of Science ®Google Scholar
• Alonzo DE, Zhang GGZ, Zhou D, et al. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res 2010;27:1–11
   PubMedGoogle Scholar
• Hodge IM. Enthalpy relaxation and recovery in amorphous materials. J Non-Cryst Solids 1994;169:211–66
   Web of Science ®Google Scholar
• Williams G, Watts DC. Non-symmetrical dielectric relaxation behaviour arising from a simple empirical decay function. Trans Faraday Soc 1970;66:80–5
   Google Scholar
• Qian F, Huang J, Hussain MA. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci 2010;99:2941–7
   PubMed Web of Science ®Google Scholar
• Ahmed A, Barry BW, Williams AC, et al. Penciclovir solubility in Eudragit films: a comparison of X-ray, thermal, microscopic and release rate techniques. J Pharm Biomed Anal 2004;34:945–56
   PubMed Web of Science ®Google Scholar
• Gupta P, Thilagavathi R, Chakraborti AK, et al. Role of molecular interaction in stability of celecoxib-PVP amorphous systems. Mol Pharm 2005;2:384–91
   PubMed Web of Science ®Google Scholar
• Theeuwes F, Hussain A, Higuchi T. Quantitative analytical method for determination of drugs dispersed in polymers using differential scanning calorimetry. J Pharm Sci 1974;63:427–9
   PubMed Web of Science ®Google Scholar
• Marsac PJ, Li T, Taylor LS. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 2009;26:139–51
   PubMed Web of Science ®Google Scholar
• Bodmeier R, Paeratakul O. Evaluation of drug-containing polymer films prepared from aqueous latexes. Pharm Res 1989;6:725–30
   PubMed Web of Science ®Google Scholar
• Jenquin MR, McGinity JW. Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions. Int J Pharm 1994;101:23–34
   Web of Science ®Google Scholar
• Malcolm RK, McCullagh SD, Woolfson AD, et al. Controlled release of a model antibacterial drug from a novel self-lubricating silicone biomaterial. J Control Release 2004;97:313–20
   PubMed Web of Science ®Google Scholar
• Gordon M, Taylor JS. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Non-crystalline copolymers. J Appl Chem 1952;2:493–500
   Web of Science ®Google Scholar
• Shamblin SL, Huang EY, Zografi G. The effects of co-lyophilized polymeric additives on the glass transition temperature and crystallization of amorphous sucrose. J Therm Anal Cal 1996;47:1567–79
   Web of Science ®Google Scholar
• Shamblin SL, Taylor LS, Zografi G. Mixing behavior of colyophilized binary systems. J Pharm Sci 1998;87:694–701
   PubMed Web of Science ®Google Scholar
• Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 2006;95:2692–705
   PubMed Web of Science ®Google Scholar
• Hancock BC, Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res 1994;11:471–7
   PubMed Web of Science ®Google Scholar
• Hirasawa N, Ishise S, Miyata H, et al. Physicochemical characterization and drug release studies of nilvadipine solid dispersions using water-insoluble polymer as a carrier. Drug Dev Ind Pharm 2003;29:339–44
   PubMed Web of Science ®Google Scholar
• Karavas E, Ktistis G, Xenakis A, et al. Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions. Drug Dev Ind Pharm 2005;31:473–89
   PubMed Web of Science ®Google Scholar
• Liu C, Wu J, Shi B, et al. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm 2006;32:115–23
   PubMed Web of Science ®Google Scholar
• Bansal SS, Kaushal AM, Bansal AK. Co-relationship of physical stability of amorphous dispersions with enthalpy relaxation. Pharmazie 2008;63:8121–4
   Google Scholar
• Bansal SS, Kaushal AM, Bansal AK. Molecular and thermodynamic aspects of solubility advantage from solid dispersions. Mol Pharm 2007;4:794–802
   PubMed Web of Science ®Google Scholar
• Kalogeras IM. Description and molecular interpretations of anomalous compositional dependences of the glass transition temperatures in binary organic mixtures. Thermochim Acta 2010;509:135–46
   Web of Science ®Google Scholar
• Chiou WL, Riegelman S. Increased dissolution rates of water-insoluble cardiac glycosides and steroids via solid dispersions in polyethylene glycol 6000. J Pharm Sci 2006;60:1569–71
   Google Scholar
• Hoffmann JD. Thermodynamic driving force in nucleation and growth processes. J Chem Phys 1958;29:1192–3
   Web of Science ®Google Scholar
• Murdande SB, Pikal MJ, Shanker RM, et al. Solubility advantage of amorphous pharmaceuticals III: is maximum solubility advantage experimentally attainable and sustainable? J Pharm Sci 2011;100:4349–56
   PubMed Web of Science ®Google Scholar
• Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281–302
   PubMed Web of Science ®Google Scholar
• Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47–60
   PubMed Web of Science ®Google Scholar
• Suhagia BN, Patel HM, Shah SA, et al. Preparation and characterization of etoricoxib-polyethylene glycol 4000 plus polyvinylpyrrolidone K30 solid dispersions. Acta Pharm 2006;56:285–98
   PubMedGoogle Scholar
• Hancock BC, Shamblin SL. Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochim Acta 2001;380:95–107
   Web of Science ®Google Scholar
• Hancock BC, Shamblin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 1995;12:799–806
   PubMed Web of Science ®Google Scholar
• Shamblin SL, Hancock BC, Dupuis Y, et al. Interpretation of relaxation time constants for amorphous pharmaceutical systems. J Pharm Sci 2000;89:417–27
   PubMed Web of Science ®Google Scholar
• Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst 2004;21:133–93
   PubMedGoogle Scholar
• Kakumanu VK, Bansal AK. Enthalpy relaxation studies of celecoxib amorphous mixtures. Pharm Res 2002;19:1873–8
   PubMed Web of Science ®Google Scholar
• DiNunzio JC, Hughey JR, Brough C, et al. Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol dispersing. Drug Dev Ind Pharm 2010;36:1064–78
   PubMed Web of Science ®Google Scholar
• Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res 2008;25:969–78
   PubMed Web of Science ®Google Scholar
• Sato T, Okada A, Sekiguchi K, et al. Difference in physico-pharmaceutical properties between crystalline and non-crystalline 9, 3-diacetylmidecamycin. Chem Pharm Bull 1981;29:2175–82
   Google Scholar
• Wu T, Sun Y, Li N, et al. Inhibiting surface crystallization of amorphous indomethacin by nanocoating. Langmuir 2007;23:5148–53
   PubMed Web of Science ®Google Scholar
• Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 2009;98:2549–72
   PubMed Web of Science ®Google Scholar
• Usui F, Maeda K, Kusai A, et al. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int J Pharm 1997;154:59–66
   Web of Science ®Google Scholar
• Stagner WC, Guillory JK. Physical characterization of solid iopanoic acid forms. J Pharm Sci 1979;68:1005–9
   PubMed Web of Science ®Google Scholar
• Karavas E, Georgarakis E, Bikiaris D. Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics. Eur J Pharm Biopharm 2006;64:115–26
   PubMed Web of Science ®Google Scholar